Sponsor or institution

Clinical trials and research at Sichuan Huiyu Pharmaceutical Co., Ltd

• 9Clinical trials
• 1Country

Newest trials

All recruiting trials (9)

• Ferric derisomaltose injection in adults with iron deficiency anemia under fasting conditions

  This study tests whether a ferric derisomaltose injection given to adults with iron deficiency anemia in a fasting state works similarly to a reference product and is safe to use.

  Recruiting Phase 1 Sichuan Huiyu Pharmaceutical Co., Ltd · Zhengzhou · NCT07790562

• Ferric Carboxymaltose Injection: Is the Chinese test product the same as Injectafer in healthy adults?

  This study tests whether a ferric carboxymaltose injection made in China behaves the same as Injectafer in healthy adults who fast.

  Recruiting Phase 1 Sichuan Huiyu Pharmaceutical Co., Ltd · Jinan · NCT07606105

• HY05350 for mesothelin-positive advanced solid tumors

  This trial will test HY05350 to see if it is safe and can help adults with mesothelin-positive advanced solid tumors after standard treatments have failed.

  Recruiting Phase 1/2 Sichuan Huiyu Pharmaceutical Co., Ltd · Beijing, Beijing Municipality · NCT07083323

• HY0001a injection for adults with advanced solid tumors

  This trial will test a new intravenous medicine called HY0001a in adults with advanced solid tumors to find safe dose levels and see if it helps control disease.

  Recruiting Phase 1/2 Sichuan Huiyu Pharmaceutical Co., Ltd · Beijing, Beijing Municipality · NCT07069062

• Comparing two forms of paclitaxel for breast cancer treatment

  This study is testing if two different forms of a breast cancer drug called paclitaxel work equally well for patients with metastatic or recurrent breast cancer.

  Recruiting Sichuan Huiyu Pharmaceutical Co., Ltd · Luoyang, Henan · NCT06765590

• Evaluating HY-2003 for reducing excessive fat under the chin

  This study is testing a new treatment called HY-2003 to see if it can safely reduce excess fat under the chin in people with moderate to severe chin fat.

  Recruiting at 2 sites Phase 1 Sichuan Huiyu Pharmaceutical Co., Ltd · Beijing, Beijing Municipality and 1 other locations · NCT06756490

• Evaluating HYP-6589 for advanced solid tumors and NSCLC

  This study is testing a new drug called HYP-6589 to see if it can safely help people with advanced solid tumors and those with advanced non-small cell lung cancer who have specific gene changes.

  Recruiting Phase 1/2 Sichuan Huiyu Pharmaceutical Co., Ltd · Guangzhou, Guangdong · NCT06712680

• Evaluating HY07121 for patients with advanced solid tumors

  This study is testing a new drug called HY07121 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting Phase 1/2 Sichuan Huiyu Pharmaceutical Co., Ltd · Jinan · NCT06639256

• Testing HYP-2090PTSA in patients with advanced solid tumors and KRAS mutations

  This study is testing a new drug called HYP-2090PTSA to see if it can safely help people with advanced solid tumors that have a KRAS mutation.

  Recruiting at 3 sites Phase 1/2 Sichuan Huiyu Pharmaceutical Co., Ltd · Fuzhou, Fujian and 5 other locations · NCT06243354

Quick answers

How many clinical trials run by Sichuan Huiyu Pharmaceutical Co., Ltd are recruiting right now?

9, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 5, Phase 1: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →